Trial Profile
Study of dalbavancin in the treatment of different gram-positive infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Gram-positive infections; Osteomyelitis; Skin and soft tissue infections
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2018 New trial record